{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Treatment Related TEAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"AEs were defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. TEAEs were defined as AEs emerging or worsening after start of treatment until 30 days after end of treatment. Adverse events were coded according to the latest available version of the Medical Dictionary for Regulatory Activities (MedDRA). Treatment-Related TEAEs was defined as any AE considered as related to study treatment.","groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle. The first three cycles are given in combination with Cisplatin at dose of 40 milligrams per square meter (mg/m2) once daily on Cycle 1 Day 2 (C1D2, C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2) With 70 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 35 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"OG000","title":"Sequence 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set (SAS) included all participants who were administered any dose of any study intervention.","reportingStatus":"POSTED","timeFrame":"Screening up to end of treatment (Day 134) and then follow up every 3 months (assessed up to maximum 6 months)","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}